SAB Biotherapeutics (SABS) Prepaid Assets (2020 - 2026)
SAB Biotherapeutics (SABS) reported Prepaid Assets of $3.8 million for Q1 2026, up 11.98% on a YoY basis from $3.4 million in Q1 2025, and up 9.17% quarter-over-quarter from $3.5 million in Q4 2025.
SAB Biotherapeutics (SABS) Prepaid Assets (2020 - 2026) Analysis & Trends
SAB Biotherapeutics has reported Prepaid Assets for 7 years, with the latest figure at $3.8 million in Q1 2026.
- For the quarter ending Q1 2026, Prepaid Assets rose 11.98% year-over-year to $3.8 million; the trailing twelve-month figure through Mar 2026 stood at $3.8 million (up 11.98% YoY), and the FY2025 full-year result was $3.5 million, up 18.03% from the prior year.
- Prepaid Assets for Q1 2026 stood at $3.8 million, up from $3.5 million in the prior quarter.
- The five-year high for Prepaid Assets was $3.8 million in Q1 2026, with the low at $702231.0 in Q3 2023.
- Historically, Prepaid Assets has averaged $2.2 million across 5 years, with a median of $2.0 million in 2024.
- Annual changes were most pronounced in 2022 — Prepaid Assets jumped 1038.56% — and 2023, when it slumped 59.57%.
- SAB Biotherapeutics' Prepaid Assets stood at $1.5 million in 2022, then surged by 56.68% to $2.3 million in 2023, then advanced by 27.16% to $3.0 million in 2024, then increased by 18.03% to $3.5 million in 2025, then gained by 9.17% to $3.8 million in 2026.
- The last three Prepaid Assets figures came in at $3.8 million (Q1 2026), $3.5 million (Q4 2025), and $1.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | SAB Biotherapeutics | 214.77 Mn | 214.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.84 Mn |
| Dec 31, 2025 | 3.51 Mn |
| Sep 30, 2025 | 1.84 Mn |
| Jun 30, 2025 | 3.59 Mn |
| Mar 31, 2025 | 3.42 Mn |
| Dec 31, 2024 | 2.98 Mn |
| Sep 30, 2024 | 2.04 Mn |
| Jun 30, 2024 | 2.03 Mn |
| Mar 31, 2024 | 2.70 Mn |
| Dec 31, 2023 | 2.34 Mn |
| Sep 30, 2023 | 702,231.00 |
| Jun 30, 2023 | 867,604.00 |
| Mar 31, 2023 | 1.21 Mn |
| Dec 31, 2022 | 1.49 Mn |
| Sep 30, 2022 | 907,865.00 |
| Jun 30, 2022 | 1.77 Mn |
| Mar 31, 2022 | 2.99 Mn |
| Dec 31, 2021 | 2.64 Mn |
| Sep 30, 2021 | 102,742.00 |
| Jun 30, 2021 | 179,867.00 |